AMAG Names Medical Affairs SVP

Carol Satler, M.D., Ph.D., has been named senior vice president of medical and scientific affairs at AMAG Pharmaceuticals, Inc. Dr. Satler has more than 25 years of healthcare experience, including 15 years in the global biopharma industry and 10 years in clinical practice. Prior to joining the company, Dr. Satler served in executive clinical development and medical affairs roles at Pfizer and Sanofi, as well as Forest Labs and Millenium. Dr. Satler led and managed teams across several therapeutics areas and held leadership roles in medical affairs, clinical R&D and administration.
 
“Carol has a long track record of success in medical affairs that will be extremely valuable to AMAG,” said William Heiden, president and chief executive officer of AMAG. “Through her 15-year career in the pharmaceutical industry, Carol has formulated and implemented medical affairs strategies and life cycle management plans for several major commercial products each with annual revenues in excess of $1 billion across a variety of indications. This experience will be invaluable to us as we prepare for the potential launch of Feraheme for the treatment of iron deficiency anemia in a broader patient population, as well as other areas of future opportunity.”